Structures of new cytotoxic bicyclic hexapeptides with a phenylpropanoid unit from Rubia cordifolia

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2025-02-01 DOI:10.1016/j.phytol.2024.12.004

Haruhiko Fukaya , Rie Kitamura , Tomoyo Hasuda , Koichi Takeya , Yutaka Aoyagi , Takahisa Nakane , Yukio Hitotsuyanagi

引用次数: 0

Abstract

Four bicyclic hexapeptides RA-XXIX–RA-XXXII, which have a phenylpropanoid unit attached to the hydroxy group of the Tyr-6 residue of deoxybouvardin, were isolated from the roots of Rubia cordifolia L. Their structures were established on the basis of spectroscopic data, the X-ray crystallography of 4-O-methyl-RA-XXIX tribromide, and the chemical conversion of RA-XXIX and RA-XXX into RA-XXXII and RA-XXXI, respectively. RA-XXIX–RA-XXXII exhibited 420–960 times and 53–330 times lower cytotoxicity than RA-VII toward the HL-60 and HCT-116 cell lines, respectively.

查看原文本刊更多论文

含苯丙类单位的新型细胞毒性双环六肽的结构

从鲁bia cordifolia L.的根中分离得到4个双环六肽RA-XXIX - RA-XXXII，这4个双环六肽在脱氧布瓦丁的tyr6残基羟基上有一个苯基丙烷基团，通过光谱数据、4- o -甲基-RA-XXIX三溴化物的x射线晶体学以及RA-XXIX和RA-XXX分别转化为RA-XXXII和RA-XXXI，建立了它们的结构。RA-XXIX-RA-XXXII对HL-60和HCT-116细胞株的细胞毒性分别比RA-VII低420 ~ 960倍和53 ~ 330倍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.